Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Sato,T.,Vries,R.G.,Snippert,H.J.,vandeWetering,M.,Barker,N.,Stange,D.E.,vanEs,J.H.,Abo,A.,Kujala,P.,Peters,P.J.,andClevers,H.(2009).Sin-gleLgr5stemcellsbuildcrypt-villusstructuresinvitrowithoutamesenchymalniche.Nature459,262–265.
Schelling,L.A.,Williamson,S.R.,Zhang,S.,Yao,J.L.,Wang,M.,Huang,J.,Montironi,R.,Lopez-Beltran,A.,Emerson,R.E.,Idrees,M.T.,etal.(2013).FrequentTMPRSS2-ERGrearrangementinprostaticsmallcellcarcinomadetectedby uorescenceinsituhybridization:thesuperiorityof uorescenceinsituhybridizationoverERGimmunohistochemistry.Hum.Pathol.44,2227–2233.
Scher,H.I.,Fizazi,K.,Saad,F.,Taplin,M.E.,Sternberg,C.N.,Miller,K.,deWit,R.,Mulders,P.,Chi,K.N.,Shore,N.D.,etal.;AFFIRMInvestigators(2012).Increasedsurvivalwithenzalutamideinprostatecancerafterchemotherapy.N.Engl.J.Med.367,1187–1197.
Sharma,A.,Yeow,W.S.,Ertel,A.,Coleman,I.,Clegg,N.,Thangavel,C.,Mor-rissey,C.,Zhang,X.,Comstock,C.E.,Witkiewicz,A.K.,etal.(2010).Theretinoblastomatumorsuppressorcontrolsandrogensignalingandhumanprostatecancerprogression.J.Clin.Invest.120,4478–4492.
Smaletz,O.,Scher,H.I.,Small,E.J.,Verbel,D.A.,McMillan,A.,Regan,K.,Kelly,W.K.,andKattan,M.W.(2002).Nomogramforoverallsurvivalofpatientswithprogressivemetastaticprostatecanceraftercastration.J.Clin.Oncol.20,3972–3982.
12Cell159,1–12,September25,2014ª2014Elsevier

Inc.
Solit,D.B.,Garraway,L.A.,Pratilas,C.A.,Sawai,A.,Getz,G.,Basso,A.,Ye,Q.,Lobo,J.M.,She,Y.,Osman,I.,etal.(2006).BRAFmutationpredictssensi-tivitytoMEKinhibition.Nature439,358–362.
Sramkoski,R.M.,Pretlow,T.G.,2nd,Giaconia,J.M.,Pretlow,T.P.,Schwartz,S.,Sy,M.S.,Marengo,S.R.,Rhim,J.S.,Zhang,D.,andJacobberger,J.W.(1999).Anewhumanprostatecarcinomacellline,22Rv1.InVitroCell.Dev.Biol.Anim.35,403–409.
Taylor,B.S.,Schultz,N.,Hieronymus,H.,Gopalan,A.,Xiao,Y.,Carver,B.S.,Arora,V.K.,Kaushik,P.,Cerami,E.,Reva,B.,etal.(2010).Integrativegenomicpro lingofhumanprostatecancer.CancerCell18,11–22.
Thatcher,N.,Chang,A.,Parikh,P.,RodriguesPereira,J.,Ciuleanu,T.,vonPa-wel,J.,Thongprasert,S.,Tan,E.H.,Pemberton,K.,Archer,V.,andCarroll,K.(2005).Ge tinibplusbestsupportivecareinpreviouslytreatedpatientswithrefractoryadvancednon-small-celllungcancer:resultsfromarandomised,placebo-controlled,multicentrestudy(IressaSurvivalEvaluationinLungCancer).Lancet366,1527–1537.
Tomlins,S.A.,Rhodes,D.R.,Yu,J.,Varambally,S.,Mehra,R.,Perner,S.,Demichelis,F.,Helgeson,B.E.,Laxman,B.,Morris,D.S.,etal.(2008).TheroleofSPINK1inETSrearrangement-negativeprostatecancers.CancerCell13,519–528.
from patients with advanced prostate, bladder, or breast cancer as well as...Regardless of whether the peptidome is derived from the tissue/microenvironment...
[6], advanced melanoma [11], prostate cancer [...from healthy donors and from patients with chronic...In DC cultures of four healthy donors, Freezing ...
热门文档